Making Alpha Therapy Possible

ABOUT ALFARIM 

AlfaRim Medical Holding BV is a Dutch privately-owned limited company originally founded by globally recognized “Father of Actinium” Dr. Ir. Maurits Geerlings. AlfaRim has developed, successfully clinically tested and patented a method of producing Actinium-225 by bombarding Radium-226 with protons in a Medium Energy Cyclotron. In doing so, AlfaRim will be able to produce and supply large quantities of Actinium-225 in predictable volumes at predictable moments in time. AlfaRim has secured its own Ra-226 stock. AlfaRim's headquarter is based in Delft, the Netherlands.

 

OUR PHILOSOPHY

WHY WE DO IT

At AlfaRim we believe in a world in which people no longer need to die from cancer or suffer unnecessarily during their treatment: a world where a cure can be found through the right combination of ingenuity, therapy and medication. It is our ambition to cure cancer.

'Imagination is more important than knowledge' - Albert Einstein

HOW WE DO IT 

Imagine that we could achieve that sick patients - even terminal patients - hear from their doctors that there is a novel therapy that could improve their quality of life, prolong their life-expectancy, or even, cure their disease? The novel therapy is called Targeted Alpha Therapy. A targeted therapy which uses Alpha emitters instead of Beta- or Chemo emitters. A therapy which is still in it's early childhood stage but is rapidly gaining attention for its potential effectiveness. We believe that Targeted Alpha Therapy is the method for curing cancer.

'It's better to believe than to disbelieve. In doing so you bring everything in the realm of possibility' - Albert Einstein

WHAT WE DO

Lack of availability of Actinium-225 represents the bottleneck in clinical development of Alpha-Isotope-based targeted therapies. Therefore, we want to make Actinium-225 available in sufficient quantities for acceptable prices and it's our ambition to be capable to supply predictable quantities Actinium-225 at predictable moments in time. Because of this we:

  1. Allow existing clinical research initiatives on Targeted Alpha Therapy to come into maturity, and
  2. Open the way towards Targeted Alpha Therapy becoming a mainstream therapy for the treatment of many types of cancer

Producing and supplying large quantities of Actinium-225 is what we will do to advance and accelerate the development of highly innovative and effective Targeted Alpha Therapies as a mainstream treatment for curing cancer.

'In the middle of difficulty lies opportunity' - Albert Einstein

 

OUR TEAM

MANAGEMENT

Hanno Mak - AlfaRim Medical Holding

Hanno Mak, MSc
Managing Director

Hanno is an entrepreneur and a former banker. During his investment banking period he was responsible for deal origination at the Equity Capital Markets- and Corporate Finance departments for amongst others Rabobank and ING in the Netherlands. At BNP Paribas Hanno was a greenfield operator and acting as Senior Banker, responsible for deal origination and development of relationships with large- and medium-sized international corporates and multinationals in the Netherlands. In addition he was Head of Clients & Sales at one of the largest independent private banks in the Netherlands. Hanno is a hands-on team builder and is specialized in management, business development, marketing and sales.

Hanno holds a Master degree in Financial Economics from the Erasmus University of Rotterdam and is a Radio Safety Worker level 5.

View profilelinkedin.com/in/hanno-mak-4406b1 


Dr. Ho Sze Chan - AlfaRim Medical Holding

Ho Sze Chan, PhD
R&D Manager - Radiochemist

Ho Sze started her PhD research project focusing on Targeted Alpha Therapy (Bismuth-213) for neuroendocrine tumours at the Erasmus Medical Centre in Rotterdam. In collaboration with Erasmus Medical Centre, she was able to perform some Bismuth-213 research at the Department of Radiopharmaceutical Sciences at the UNM Health Sciences Center of the University of New Mexico in Albuquerque, USA. Also, she spent time at Mallinckrodt Pharmaceuticals in Petten. Prior to leaving the scientific sector for joining AlfaRim, Ho Sze was at the Department of Radiology of the University of Pennsylvania in Philadelphia, where she worked as a postdoctoral researcher on the improvement of Astatine-211 production.

Ho Sze studied Theoretical & Physical Chemistry at the University of Leiden and received a PhD from the Department of Radiology and Nuclear Medicine of the Erasmus University of Rotterdam. As a Radiochemist and a Radiation Safety Worker (level 3), Ho Sze has, besides Alphas, also a lot of experience in working with other radionuclides.

View profile: linkedin.com/in/ho-sze-chan-98945b12


Rory M.S. de Zanger, B Eng
Lead Physicist

During his Bachelors program of Applied Physics, Rory worked as a research analyst at the Department of Radiology and Nuclear Medicine of the Erasmus Medical Centre in Rotterdam. After the completion of an internship at the Reactor Institute Delft, part of the Delft University of Technology, he became a Machine Father in the Beam Generator Team at Mapper Lithography in Delft. Two years later Rory re-joined the Radiology and Nuclear Medicine department at Erasmus MC where he stayed for another three years as Researcher/ Physicist. Prior to joining AlfaRim as Lead Physicist, Rory worked almost two years for the Dutch Organisation for Applied Scientific Research (TNO) in Delft as a researcher and experimentalist at the Nano-Instrumentation department.

Rory graduated as an Engineer in Engineering Physics from The Hague University of Applied Science located on campus of the TU Delft. Besides being a Physicist, Rory is also a Radiochemist and a Radiation Safety Worker (level 3) with experience in a wide range of isotopes.

View profilelinkedin.com/in/rory-de-zanger-85250049


Elisa Barroso, PhD
MAIT Manager

Elisa started her career as scientific researcher at the Institute of Science and Innovation in Mechanical and Industrial Engineering in Porto and the Institute of Molecular Pathology and Immunology of the University of Porto where she worked a.o. on the development of software for the visualization and analysis of mass-spectrometry data and contaminants detection of mass-spectrometry data. In 2013 Elisa joined the Erasmus Medical Centre in Rotterdam where she developed Raman spectroscopy-based tools for surgical guidance in head and neck oncology and worked as Technical Project Manager. At AlfaRim, Elisa is responsible for the oversight on the Manufacturing, Assembly, Integration and Testing of AlfaRim’s custom-made production equipment. 

Elisa holds a Master degree in Biomedical Engineering from the faculty of Engineering from the University of Porto and holds a PhD from the Erasmus University in Rotterdam.

View profile: linkedin.com/in/elisa-barroso-ab4a7240


Mark A.W. de Zeeuw, MSc
Program Manager

Starting as a business analyst in the venture capital industry, Mark specialised in the management of business programs and the reporting on budget programs for innovative technical development projects. Over the years he worked on projects in several industires such the medTech-, mechanics-, composites-, IT software- and the electronics-hardware industry. Prior to joining AlfaRim, Mark was a consultant for Sira Incentives in Amsterdam, an advisory firm amongst others specialised in the fields of independent advice on local and international (EU) subsidy programs as well as funding application writing & submission for clients.

Mark holds a Master degree in International Business Administration, Strategy & Organisation from the VU Amsterdam. In addition, Mark holds a minor degree in the Master program of Materials Science and Engineering from the  Technical University of Delft (TU Delft). Mark is a Radio Safety Worker level 5.

View profilelinkedin.com/in/mark-de-zeeuw-7624a8b


SUPERVISORY BOARD

Nico Bruijel - AlfaRim Medical Holding

Nico J. Bruijel, Msc
Chairman of the Supervisory Board

Nico is a former member of the Executive Board of Royal Philips Electronics. At Philips, Nico served as Divisional Director of the Philips division Elcoma in the UK, as Technical/ Industrial Director of Philips Brazil, as CEO of the Philips Lighting Electronics Division in the Netherlands, as President and CEO of Philips Lighting Inc. Americas in the US and as President and CEO of Philips Japan. In the Executive Board, Nico was responsible for group-wide regional and country operations as well as Human Resources Management. After leaving Philips, Nico served as COO of Osaka based listed Sunstar Inc. in Japan. Prior to Philips, Nico worked at DSM in the Netherlands.

Nico has an Industrial Engineering background and a Master degree in Behavioral Science from the University of Utrecht in the Netherlands.



Dr. Ir. Maurits Geerlings - AlfaRim Medical Holding

Dr. Ir. Maurits W. Geerlings
Member of the Supervisory Board

Maurits is a former member of the Executive Board of Akzo Nobel but started his career as a lieutenant at the Dutch Royal Airforce. Later he attended the International School for Nuclear Reactor Engineering in Raleigh, NC and Argonne Nat.Lab, IL in the USA. Hereafter he spent two years in the Netherlands at Comprimo, a chemical engineering firm after which he joined Euratom’s Joint Research Center, stationed initially in Brussels and France and later in Karlsruhe, Germany to set up and head the Nuclear Chemistry departments. After 10 years at Euratom, Maurits joined Akzo Nobel first as head of the process analysis and debottlenecking department of Engineering in Hengelo and Arnhem the Netherlands, followed by an appointment at the Akzo Pharma Division. Thereafter, Maurits was appointed to the Akzo Board of Management (later the Management Committee) as member in charge of Research and Technology for the corporation''. 

Since his retirement he continued to develop the concept of ‘’α-particle radio immuno therapy’’ for ceDllular diseases, in particular cancer. He is the author of major patents regarding the utilization of radioisotopes and the process for making Actinium-225 and Bismuth-213 using the nuclear reaction of Ra-226(p,2n) Ac-225 with a cyclotron to raise the 15-20 MeV protons. Maurits studied at the Technical University of Delft in the Netherlands and holds a PhD in Chemical Engineering.


Daan van der Vorm, MSc, MRE
Member of the Supervisory Board

Daan is CEO of Vorm Holding, a Rotterdam based company active in non-residential construction, renovation and residential construction. An important part of the turnover comes from own project development, especially in the field of residential construction and commercial real estate. Daan is also the founder and owner of NEXT Real Estate B.V., a real estate operating company in Papendrecht. Houses, retail spaces and office spaces are managed from this company. Daan is a Certified Board Member from the Dutch Association of Board Members and Supervisory Board Members. Besides a seat in the AlfaRim Supervisory Board, he holds a supervisory board seat at SWK (Dutch Housing Guaranty & Warranty Foundation) and at BOEI (foundation for Dutch Industrial Heritage Buildings). 

Daan holds a Master degree in Business Administration from the Erasmus University in Rotterdam and is a Master of Real Estate. 

View profilelinkedin.com/in/daanvandervorm


 


ABOUT ALFARIM

AlfaRim Medical Holding BV is a Dutch privately-owned limited company originally founded by globally recognized "Father of Actinium" Dr. Ir. Maurits Geerlings. Learn more about what drives us and meet our team. Read more

ABOUT ACTINIUM-225

Actinium-225 is an isotope of Actinium and is used in nuclear medicine in the treatment of cancer. Actinium-225 itself and its decay products emit alpha particles which destroy cancerous cells in the body. Read more

ABOUT ALPHA THERAPY

Today, targeted radiotherapies only make use of so-called Beta-isotopes. Novel and breakthrough clinical research has proven that targeted therapies using Alpha-isotopes can be much more effective. Read more